Panel Recommends Listing 9 Substances in Carcinogen Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ARLINGTON, Va-A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on

 ARLINGTON, Va—A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on Carcinogens,” prepared by the National Toxicology Program (NTP) and scheduled for publication in 2002.

The panel voted to upgrade beryllium and beryllium compounds (substances used in fiber optics, aerospace, and other industrial applications) from “reasonably anticipated” to “known” human carcinogens. They recommended listing vinyl bromide and vinyl fluoride as “known” human carcinogens. Vinyl bromide’s primary use is in making flame-retardant synthetic fibers. Vinyl fluoride is a chemical used in making polyvinylfluoride, which is used in the plastics industry.

The panel also recommended listing two other chemicals used in make products flame resistant as “reasonable anticipated” to be human carcinogens: 2,2-bis-(bromomethyl)l-1,3-propanediol used in unsaturated polyester resins, molded products, and rigid polyurethane foam, and 2,3-dibromo-1-propanol, also found in pesticides and drug preparations.

Three other substances were cited as “reasonably anticipated” to be human carcinogens: dimethylbenzidine dyes used in some textiles and plastics; IQ, found in cooked meat and fish; and styrene-7,8-oxide, use in preparing fragrances.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content